Fab Phage Display Library
The interest in antibodies, both as tools for generating new knowledge or as medical interventions to address health concerns, continues to grow. The Phage Display System is a well-established technology to fulfill this growing interest. This technology provides both molecular diversity and high throughput capacity allowing the selection of antibodies with high affinity and specificity for almost any target.
To accomplish its goal in the development of therapeutic antibodies, in June 2019, the Indiana Biosciences Research Institute (IBRI) entered into a licensing agreement with Eli Lilly and Company to gain access to its proprietary human Fab Phage Display Library platform. This platform is a combination of multiple libraries representing vast molecular diversity.
Access to Lilly’s Phage Display platform is a significant enhancement to the IBRI’s capabilities in the discovery and development of novel antibodies. In addition to its internal efforts, the IBRI will establish partnerships to utilize the library for developing new diagnostic tools and therapeutic interventions for a range of disease targets. Through the licensing of its library, Lilly is hopeful that the IBRI and its partners can make meaningful therapeutic advancements that lead to improved health for patients.
Bioanalytical Technologies' mission is to support the IBRI's research areas by helping to innovate the next generation of bioanalytical systems and methods. These efforts support and help enable the IBRI's development of new standards of patient care and therapeutics.
More about Bioanalytical Technologies
The IBRI has a Metabolic Mouse Phenotyping Core designed to provide an array of sophisticated research techniques for the purpose of investigating mouse models of human disease. The core advances medical and biological research by providing researchers with comprehensive, standardized and high quality metabolic phenotyping services for mouse models of diabetes, diabetic complications, obesity and related disorders.
The core utilizes the TSE System metabolic caging for up to 16 mice that includes indirect calorimetry, food and water intake and activity measurements. The core also offers services that include EcoMRI, GTT, ITT, islet isolation, GSIS and tissue procurement. For more information about metabolic phenotyping at the IBRI, please contact Natalie Stull.
Terms and Conditions
The IBRI Zebrafish Core Facility is a shared resource that provides researchers with the ability to utilize the zebrafish model organism in their studies. Zebrafish have several advantages over other model organisms including ease of genetic manipulation, a sequenced genome, rapid external development, high fecundity, extensive regenerative capabilities, and straightforward husbandry requirements. Our facility has the capacity for 120 tanks, with an expanding complement of transgenic models. This facility will assist our researchers and collaborators as they work to better understand human development and diseases by providing access to a unique tool by which molecular mechanisms can be explored in vivo.
The Microscopy Core houses state-of-the-art microscopy equipment with related imaging acquisition software for use by IBRI researchers and collaborative projects. Currently the Core contains a Zeiss LSM 710 confocal microscope with capacity for high resolution imaging, a Leica M205 fluorescent dissecting microscope with a camera for wholemount imaging, and two Leica M80 dissecting microscopes outfitted with cameras and video monitors to provide teaching and interactive learning capabilities.
The IBRI Cell Culture Facility supports research studies that require the culture of human and/or animal-derived primary and immortalized cells. The facility contains all necessary equipment to facilitate this in vitro culture work including, but not limited to, cellular analysis, manipulation, and microscopy.
Fairbanks Institute Tissue
Originally funded with a $10 million gift from the Indianapolis-based Richard M. Fairbanks Foundation in 2006, the Fairbanks Institute created a next generation biorepository as a resource for research on chronic diseases of aging. INBankTM enrolled participants in what was at the time a unique long-term health study that linked biological samples with participants’ real-time medical histories, allowing tracking of the progression and complications of the disease over time. The IBRI now houses a replica of that biorepository of roughly 17,000 samples with the ability to connect those samples to longitudinal medical data for purposes of research.